[abnormal analysis] running out of stock has become the norm. The global market for this "slimming medicine" is in short supply. Sales in the first quarter increased by more than 200% compared with the same period last year. According to the list of relevant listed companies (attached table), this enterprise has laid out related injection products.

Running out of stock has become the norm. The global market for this "slimming god drug" is in short supply. Sales in the first quarter increased by more than 200% compared with the same period last year. According to the list of relevant listed companies (attached), this enterprise has laid out relevant injection products and plans to enter the Ⅲ phase clinical trial in the second half of this year. Another enterprise focuses on planning and laying out a number of GLP-1 peptide drugs.